浙江新光药业股份有限公司 第二章 人员组成 第四条 薪酬与考核委员会成员由三名董事组成，其中独立董事不少于二名。 第五条 薪酬与考核委员会委员由董事会选举产生，委员会设召集人一名， 由董事会选举一名独立董事委员担任，负责主持委员会工作。 第六条 薪酬与考核委员会委员必须符合下列条件： （一）不具有《公司法》或《公司章程》规定的不得担任公司董事、监事、 高级管理人员的禁止性情形； 董事会薪酬与考核委员会议事规则 第一章 总则 第一条 为进一步建立健全公司董事（非独立董事）及高级管理人员的考核 和薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司法》、《上市公 司治理准则》、《公司章程》及其他有关规定，公司特设立董事会薪酬与考核委员 会，并制订本议事规则。 第二条 董事会薪酬与考核委员会是董事会依据相应法律法规设立的专门工 作机构，主要负责制定公司董事及高级管理人员的考核标准并进行考核；负责制 定、审查公司董事及高级管理人员的薪酬政策与方案，对董事会负责。 第三条 本规则所称董事是指在本公司支取薪酬的董事长、董事，高级管理 人员是指董事会聘任的总经理、副总经理、财务总监、董事会秘书及由总经理提 请董事会认定 ...

浙江新光药业股份有限公司 独立董事专门会议工作制度 第一章 总 则 第一条 为进一步建立健全浙江新光药业股份有限公司（以下简称"公司"）的 治理结构，充分发挥独立董事在公司治理中的作用，根据《中华人民共和国公司法》 《上市公司治理准则》《上市公司独立董事管理办法》《浙江新光药业股份有限公 司章程》（以下简称"《公司章程》"）及其他有关规定，公司特制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其主要股 东、实际控制人不存在直接或间接利害关系，或者其他可能影响其进行独立客观判 断关系的董事。 第三条 独立董事专门会议是指全部由独立董事参加的专门会议。 第四条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、行政 法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、深圳证券交易 所业务规则和《公司章程》的规定，认真履行职责，在董事会中发挥参与决策、监 督制衡、专业咨询作用，维护公司整体利益，保护中小股东合法权益。 第二章 职责权限 第五条 独立董事行使以下特别职权前应经公司独立董事专门会议审议，并经全 体独立董事过半数同意： （一）独立聘请中介机构，对公司具体事项进行 ...

浙江新光药业股份有限公司董事会提名委员会 关于独立董事独立性情况的专项意见 浙江新光药业股份有限公司董事会 提名委员会 2024 年 4 月 18 日 根据中国证监会《上市公司独立董事管理办法》、《深圳证券交易所股票上 市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等要求，浙江新光药业股份有限公司（以下简称"公司"）董事会， 就公司在任独立董事宋夏云、王虎根、祝明及候选独立董事蔡海静的独立性情况 进行评估并出具如下专项意见： 经核查，公司在任独立董事宋夏云、王虎根、祝明及候选独立董事蔡海静的 任职经历以及签署的相关自查文件，上述人员未在公司担任除独立董事以外的任 何职务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存 在利害关系或其他可能妨碍其进行独立客观判断的关系，因此，公司独立董事符 合《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》中对独立董事独立性的相关要求。 ...

浙江新光药业股份有限公司 2023 年度独立董事述职报告 独立董事 宋夏云 各位股东及股东代表： 本人作为浙江新光药业股份有限公司（以下简称"公司"）第四届董事会独 立董事及第四届董事会审计委员会主任委员、薪酬与考核委员会委员，在 2023 年度工作中，本着客观、公正、独立的原则，严格按照《公司法》、《证券法》、 《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规及《公司章程》和《独立董事工 作制度》的规定，勤勉尽责，积极发挥独立董事作用，维护公司整体利益和全体 股东的合法权益。现将本人 2023 年度履行独立董事职责情况总结如下： 一、出席会议情况： 二、发表独立意见情况： 作为公司独立董事，本人恪尽职守、勤勉尽责，根据法律、法规和相关规 章 制度的规定，对公司定期报告、募集资金存放与使用情况、控股股东及其他关 联方占用公司资金、公司对外担保情况等有关事项发表了独立意见，对董事会 决策的科学性和客观性及公司的良性发展都起到了积极的作用。 2023 年度，公司董事会共召开 5 次会议，召开股东大会 1 次、审计委员会会 议 4 次、薪酬与考核委 ...

持股 5%以上的股东嵊州市和丰投资股份有限公司保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"本公司"或"公司"）就持股 5%以上 股东嵊州市和丰投资股份有限公司（以下简称"和丰投资"）拟减持公司股份的意 向预披露了《关于持股 5%以上股东股份减持计划期限届满及未来减持计划预披露的 公告》（公告编号：2023-028），和丰投资拟通过集中竞价交易方式减持公司股份 合计不超过公司总股本比例 2.00%。 近日，公司收到股东和丰投资提交的《关于股份减持计划期限届满的告知函》， 本次减持股份计划期限届满。在本次减持计划期间，和丰投资通过深圳证券交易所 以集中竞价方式共减持公司股份 670,000 股（占公司总股本比例 0.4188%）。 根据《上市公司股东、董监高减持股份的若干规定》（证监会公告[2017]9 号） 及《深圳证券交易所上市公司股东及董事、监事、高级管理人员减持股份实施细则》 的相关规定，现将和丰投资股份减持计划实施情况公告如下： 证 ...

Financial Performance - The company's revenue for Q3 2023 was ¥67,075,377.49, a decrease of 27.08% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥20,160,102.38, down 29.49% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥19,593,617.82, reflecting a 31.98% decline compared to the previous year[5] - Total operating revenue for the third quarter was CNY 216.11 million, a decrease of 17.7% compared to CNY 262.45 million in the same period last year[19] - Net profit for the third quarter was CNY 58.70 million, representing a decline of 34.3% from CNY 89.40 million in the previous year[20] - Earnings per share for the third quarter were CNY 0.37, down from CNY 0.56 in the same quarter last year[20] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥919,269,079.44, a decrease of 4.02% from the end of the previous year[5] - The company's total current assets as of September 30, 2023, amount to ¥777,543,459.59, a decrease from ¥812,262,950.53 at the beginning of the year[16] - The total assets of the company as of September 30, 2023, are ¥919,269,079.44, down from ¥957,759,191.66 at the start of the year[16] - The total liabilities of the company as of September 30, 2023, are ¥71,211,819.77, a decrease from ¥88,367,651.86 at the beginning of the year[16] - Total liabilities amounted to CNY 81.25 million, a decrease from CNY 98.86 million in the previous year[20] Cash Flow - Cash flow from operating activities for the year-to-date was ¥41,748,650.66, a significant decrease of 55.36% compared to the same period last year[5] - Cash flow from operating activities generated a net amount of CNY 41.75 million, significantly lower than CNY 93.52 million in the previous year[22] - The net cash flow from investing activities increased by 143.37% to ¥20,486,792.61, mainly due to increased redemption of financial products[9] - The company reported a net cash flow from investment activities of CNY 20.49 million, an increase from CNY 8.42 million year-over-year[22] - Cash flow from financing activities decreased to -80 million from -96 million year-over-year[23] - The net increase in cash and cash equivalents was -17.76 million compared to an increase of 5.94 million in the previous year[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,152[10] - The largest shareholder, Wang Yuejun, holds 38.25% of the shares, totaling 61,200,000 shares[10] - The number of restricted shares held by Wang Yuejun remains at 45,900,000, with no shares released during the period[13] - The company has no preferred shareholders as indicated in the report[12] Inventory and Receivables - Accounts receivable decreased by 30.82% to ¥16,467,773.43 due to reduced shipments compared to the previous year[8] - Inventory increased by 29.93% to ¥59,957,414.26, attributed to decreased shipments at the end of the reporting period[8] - The inventory level has increased to ¥59,957,414.26 from ¥46,146,719.95 at the beginning of the year[15] Financial Expenses and Equity - The company reported a 54.12% increase in financial expenses, totaling -¥13,066,151.75, primarily due to increased bank deposit interest[8] - The total equity attributable to shareholders was CNY 838.02 million, down from CNY 858.89 million year-over-year[20] - Deferred income tax liabilities increased to CNY 502.06 million from CNY 426.23 million in the previous year[20] Strategic Developments - The company has not reported any new strategies or significant market expansions in the current quarter[14]

证券代码：300519 独立董事发表的独立意见 浙江新光药业股份有限公司独立董事关于 第四届董事会第十二次会议相关事项发表的独立意见 浙江新光药业股份有限公司（以下简称"公司"）于 2023 年 10 月 23 日召 开第四届董事会第十二次会议，根据相关法律、法规、规范性文件及公司章程的 规定， 我们作为公司独立董事，基于独立、客观、公正的立场，对会议审议的 相关事项发表独立意见如下： 证券代码：300519 独立董事发表的独立意见 （本页无正文，为浙江新光药业股份有限公司独立董事关于第四届董事会第十二 次会议相关事项发表的独立意见签字页） 一、关于 2023 年第三季度报告全文的独立意见 经核查，我们认为：董事会编制和审核《公司 2023 年第三季度报告全文》 的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地 反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 二、关于公司 2023 年第三季度关联交易事项的独立意见 经核查，我们认为：报告期内，公司未发生重大关联交易行为。 三、关于控股股东及其他关联方资金占用和对外担保事项的独立意见 经核查，我们认为：报告期内，公司控 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥149,038,556.10, a decrease of 12.57% compared to ¥170,464,124.83 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2023 was ¥38,539,667.00, down 36.62% from ¥60,804,863.66 in the previous year[19]. - Basic earnings per share for the first half of 2023 were ¥0.24, a decline of 36.84% from ¥0.38 in the previous year[19]. - Operating profit decreased by 36.55% to ¥45,334,468.29 from ¥71,450,894.51 year-on-year, primarily due to reduced revenue and increased raw material costs[35]. - The total comprehensive income decreased by 36.06% to ¥38,874,107.27 from ¥60,801,527.94 in the same period last year[36]. - The company's net profit for the first half of 2023 is CNY 38,539,667, a decrease of 36.5% compared to CNY 60,804,863 in the same period of 2022[131]. - The total revenue for the first half of 2023 is CNY 148,490,166.82, down from CNY 170,464,124.83 in the first half of 2022, representing a decline of 12.9%[133]. - The company's financial expenses showed a significant improvement, with a net financial expense of CNY -2,715,615.94 compared to CNY -7,610,282.85 in the previous year[131]. Cash Flow and Investments - The net cash flow from operating activities decreased by 58.28%, amounting to ¥29,193,593.04 compared to ¥69,982,644.10 in the same period last year[19]. - The company reported a significant increase in cash and cash equivalents net decrease of 340.53%, amounting to -¥75,958,161.24 compared to -¥17,242,412.86 last year[35]. - The company's cash flow from investing activities showed a net outflow of -¥25,151,754.28, a decrease of 386.63% compared to a net inflow of ¥8,774,943.04 last year, primarily due to increased purchases of bank wealth management products[35]. - The total cash outflow for investment activities was CNY 317,302,981.68, which is an increase of 25% from CNY 253,840,022.09 in the first half of 2022[137]. - The company received CNY 260,000,000.00 from other investment activities, an increase of 36.8% compared to CNY 190,000,000.00 in the previous year[138]. Assets and Liabilities - Total assets at the end of the reporting period were ¥895,933,532.48, representing a decrease of 6.46% from ¥957,759,191.66 at the end of the previous year[19]. - The net assets attributable to shareholders decreased by 4.79%, totaling ¥817,768,658.50 compared to ¥858,894,551.23 at the end of the previous year[19]. - The total current assets as of June 30, 2023, amount to 755,805,204.11 CNY, a decrease from 812,262,950.53 CNY at the beginning of the year[123]. - Total liabilities decreased from CNY 98,864,640.43 to CNY 78,164,873.98, a reduction of about 20.83%[125]. - Owner's equity decreased from CNY 858,894,551.23 to CNY 817,768,658.50, a decline of approximately 4.79%[125]. Research and Development - Research and development expenses increased by 4.08% to ¥7,673,241.07 from ¥7,372,575.98 year-on-year[35]. - The company has established a provincial-level high-tech research and development center and collaborates with several universities for product innovation, holding 11 core independent intellectual property rights[31][32]. - The company plans to establish a wholly-owned subsidiary, Zhejiang Xinguang Pharmaceutical Technology Co., Ltd., in Hangzhou to enhance R&D efficiency and attract high-end technical talent[47]. - The company has committed to increasing R&D investment in response to significant changes in the pharmaceutical industry policies, focusing on the creation of new traditional Chinese medicines[47]. Market and Product Strategy - The company primarily engages in the research, production, and sales of traditional Chinese medicine, chemical drugs, and health foods, focusing on cardiovascular diseases and other medical areas[27]. - Key products include Huangqi Shengmai Drink, Shenjindan Capsules, and American Ginseng Oral Liquid, with Huangqi Shengmai Drink being particularly noted for its efficacy in treating coronary heart disease[27][30]. - The company has developed sugar-free versions of its products to cater to the growing market of diabetes patients, indicating a proactive approach to market demands[30]. - The company is expanding its market presence in Asia, targeting a 5% increase in market share by the end of the year[53]. - New product launches are expected to contribute an additional 1 billion in revenue over the next fiscal year[53]. Risk Management - The company faces risks related to industry policy changes, medical insurance policy changes, and fluctuations in raw material prices[3]. - The company emphasizes the importance of risk awareness among investors regarding future plans and forecasts[3]. - The company will actively monitor potential risks and take timely measures to achieve its operational goals for 2023[3]. - The company faces pressures from price reductions due to national healthcare reforms and centralized procurement, impacting future sales strategies[29]. - The company faces risks from fluctuating raw material prices, particularly for key Chinese medicinal herbs[64]. Corporate Governance and Compliance - The company has not engaged in any significant litigation or arbitration matters during the reporting period[88]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[84]. - The company has not issued any non-standard audit reports for the current or previous periods[87]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[112]. - The financial report for the first half of the year has not been audited[121]. Social Responsibility and Sustainability - The company emphasizes its commitment to social responsibility and aims to enhance human life quality while promoting the health industry[80]. - The company plans to invest 5% of its revenue into sustainability initiatives over the next three years[53]. - The company has implemented a complete environmental monitoring plan and has not exceeded pollution discharge standards[78].

编制单位：浙江新光药业股份有限公司 单位：人民币万元 | 非经营性资金占用 | 资金占用方名 | 占用方与上市公 | 上市公司核算 | 2023 年期初 | 2023 年 1-6 月占 用累计发生金额 | 2023 年 1-6 月占 用资金的利息 | 2023 年 1-6 月 偿还累计发生 | 2023 年 6 | 月末 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 称 | 司的关联关系 | 的会计科目 | 占用资金余额 | （不含利息） | （如有） | 金额 | 占用资金余额 | | 原因 | | | 控股股东、实际控制 | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | 小 计 | | | | | | | | | | | | | 前控股股东、实际控 | | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | | 小 计 | | | | | ...

证券代码：300519 证券简称：新光药业 公告编号：2023-032 浙江新光药业股份有限公司 第四届董事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长王岳钧先生召集，会议通知于 2023 年 8 月 16 日以 专人送达、电子邮件、电话等形式送达全体董事，董事会会议通知中包括会议的 相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2023 年 8 月 23 日在浙江省嵊州市剡湖街道环城西路 25 号公司三楼会议室召开，采取现场投票和通讯表决相结合的方式进行表决。 3、本次会议应出席董事 9 名，实际出席董事 9 名，其中宋夏云、王虎根、 祝明等三位董事采用通讯方式参加会议并表决。 4、本次会议由董事长王岳钧先生召集及主持，公司监事及高级管理人员列 席了会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等相 关法律法规和公司章程的规定。 二、董事会会议审议情况 表决结果：9 票赞成，0 票反对，0 票弃权。 公司《2023 年半年度报告》全文 ...